Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05627882 · ClinicalTrials.gov registry record
Evaluation of the Impact of a Forward Viewing Scope at Time of ERCP
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 163
- Enrollment target
NCT05627882: Completed study, sponsored by Brigham and Women's Hospital.
NCT05627882 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05627882 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 163 participants
- Enrollment target
Study Summary
This study will be a prospective, tandem-designed study to determine the proportion of clinically significant missed lesions when using a side- or oblique-viewing endoscope as compared to the standard forward-viewing endoscope. Utilizing standard endoscopy protocols in current practice at Brigham and Women's Hospital, consecutive adult patients undergoing ERCP for traditional reasons will undergo back-to-back tandem EGD and ERCP examinations. This process entails an EGD performed by an attending gastroenterologist first. Next, a second blinded attending gastroenterologist will perform ERCP immediately after index EGD. Both endoscopists will note any clinically significant findings, independent of the other providers procedural findings. Clinically significant findings defined as endoscopic findings that alter patient management (i.e., esophageal varices, peptic ulcer disease, hemorrhage, mass, etc.) during EGD and ERCP will be recorded. As previously stated, some institutions already routinely perform EGD with every ERCP.
Primary Outcome
Endoscopic findings that alter medical/procedural management including: erosive disease, Barrett's esophagus, peptic ulcer, gastrointestinal malignancy, other.
Interventions
- DIAGNOSTIC_TEST Forward viewing endoscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2024-07-01 |
What the finished NCT05627882 record still lists
NCT05627882 is an observational study that tracks outcomes without assigning an intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Forward viewing endoscope is the first listed.
NCT05627882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05627882 about?
NCT05627882 is a clinical study titled "Evaluation of the Impact of a Forward Viewing Scope at Time of ERCP". This study will be a prospective, tandem-designed study to determine the proportion of clinically significant missed lesions when using a side- or oblique-viewing endoscope as compared to the standard forward-viewing endoscope. Utilizing standard endoscopy protocols in current practice at Brigham an...
What is the current status of trial NCT05627882?
This trial is currently completed. The enrollment target is 163 participants. The study started on 2022-10-14. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT05627882?
The interventions under investigation include: Forward viewing endoscope (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05627882?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI